![Michael K. Brawer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael K. Brawer
Keine laufenden Positionen mehr
Karriereverlauf von Michael K. Brawer
Ehemalige bekannte Positionen von Michael K. Brawer
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MDXHEALTH SA | Technik-/Wissenschafts-/F&E-Leiter | 06.09.2017 | 14.12.2018 |
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2003 | 02.11.2007 |
Northwest Prostate Institute | Direktor/Vorstandsmitglied | - | - |
MYRIAD GENETICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Michael K. Brawer
University of California, Los Angeles | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Belgien | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MDXHEALTH SA | Health Technology |
MYRIAD GENETICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Northwest Prostate Institute |
- Börse
- Insiders
- Michael K. Brawer
- Erfahrung